ArticleSurgical endoscopy2026
National trend and impact of compensated cirrhosis in patients who underwent metabolic and bariatric surgery: a Nationwide Readmissions Database study.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is still a lack of sufficient data regarding the trend of cirrhosis and its impact on the perioperative and postoperative outcomes, and healthcare resource utilization in patients who underwent metabolic and bariatric surgery (MBS). Therefore, our study aimed to examine the impact of cirrhosis on MBS outcomes.
methodsThe current study used the Nationwide Readmissions Database (NRD) 2016-2020. Patients who underwent MBS were divided into cirrhosis and non-cirrhosis groups. Patients younger than 18 years, those with a history of upper gastrointestinal malignancy, and patients with decompensated cirrhosis (portal hypertension, ascites, or varices) and individuals with a previous history of MBS were excluded.
resultsThe cirrhosis and non-cirrhosis groups consisted of 3064 and 538,329 patients, respectively. There was no significant change in the cirrhosis trend in patients who underwent MBS from 2016 to 2020. Cirrhosis was not associated with higher rates of in-hospital mortality (< 11 (< 0.36%) vs 99 (0.02%), p = 0.140), 90-day readmission (180 (6.57%) vs 24,204 (5.01%), p = 0.453), or most major complications. Although the overall incidence was low, cirrhosis was linked to higher rates of hepatic encephalopathy and acute heart failure. Patients with cirrhosis also had longer hospital stays, higher costs, and were more likely to have a non-home discharge. Among patients with cirrhosis, Roux-en-Y gastric bypass (OR 1.63, 95% CI 1.18-2.25, p = 0.003) and duodenal switch (OR 3.54, 95% CI 1.42-8.85, p = 0.007) were associated with a higher readmission rates compared to sleeve gastrectomy.
conclusionThese results may indicate the safety of MBS in patients with compensated cirrhosis and obesity.
Indexed as
Identifiers
41514130What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.